Cited by 26Prostate Cancer Treatment and ResearchPI3K/AKT/mTOR signaling in cancerCRISPR and Genetic Engineering

Generation of PTEN-knockout (-/-) murine prostate cancer cells using the CRISPR/Cas9 system and comprehensive gene expression profiling

Open access
Takao, Akiko, Yoshikawa, Kazuhiro, Karnan, Sivasundaram, Ota, Akinobu, Uemura, Hirotsugu, De Velasco, Marco, Kura, Yurie, Suzuki, Susumu +3 more·2018·Oncology Reports

Abstract

Phosphatase and tensin homolog (PTEN) deficiency is associated with development, progression, and metastasis of various cancers. However, changes in gene expression associated with PTEN deficiency have not been fully characterized. To explore genes with altered expression in PTEN‑deficient cells, the present study generated a PTEN‑knockout cell line (ΔPTEN) from a mouse prostate cancer‑derived cell line using the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR‑associated protein 9 (CRISPR/Cas9) gene editing system. Following transfection of the CRISPR/Cas9 construct, DNA sequencing was performed to identify deletion of the Pten locus and PTEN inactivation was verified by western blotting. The ΔPTEN cell line exhibited enhanced RAC‑alpha serine/threonine‑protein kinase phosphorylation and cyclin D1 expression. In addition, an increase in cell proliferation and colony formation was observed in the ΔPTEN cell line. Gene expression profiling experiments were analyzed with microarray and microRNA (miRNA) arrays. In the microarray analysis, 111 genes exhibited ≥10‑fold increased expression compared with the parent strain and mock cell line and 23 genes were downregulated. The only miRNA with increased expression of 10‑fold or more was mmu‑miR‑210‑3p. Genes with enhanced expression included genes involved in the development, progression, and metastasis of cancer such as Tet methylcytosine dioxygenase 1, twist family BHLH transcription factor 2, C‑fos‑induced growth factor and Wingless‑Type MMTV Integration Site Family, Member 3, and genes involved in immunosuppression such as Arginase 1. The results of the present study suggest that PTEN deficiency mobilizes a variety of genes critical for cancer cell survival and host immune evasion.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/or.2018.6683

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Takao, A., Yoshikawa, K., Karnan, S., Ota, A., Uemura, H., De Velasco, M., Kura, Y., Suzuki, S., Ueda, R., Nishino, T., & Hosokawa, Y.
Affiliations
  • Aichi Medical University (JP)
  • Kindai University (JP)
  • Department of Genome Biology, Kindai University Faculty of Medicine, Osaka‑Sayama, Osaka 589‑8511, Japan
Venue
Oncology Reports
Published
2018-09-05
Volume
40
Issue
5
Pages
2455-2466
ISSN
  • 1021-335X (ISSN-L)
  • 1791-2431
OpenAlex
W2891174394
Cited by
26
References
1
Citations by year
2025: 3 · 2024: 7 · 2023: 3 · 2022: 4 · 2021: 4 · 2020: 3 · 2019: 2
FWCI
1.71
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Oncology Reports (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science (17K11165, 18K08342)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Keywords
PTEN loss, prostate cancer, CRISPR/Cas9 knockout, gene expression profiling, microRNA, miR-210-3p, cyclin D1, cell proliferation, colony formation, tumor immunosuppression, arginase-1, TET1, TWIST1, Wnt3, metastasis
MeSH terms
Animals, Humans, Immunity, Cellular, Male, Prostate, Prostatic Neoplasms, Genetic Therapy, Gene Expression Regulation, Neoplastic, MicroRNAs, Cell Line, Tumor, Microarray Analysis, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Mice, Gene Knockout Techniques, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review